在实验性癌症治疗中使用氨酸和化疗化合物
1Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, 44 Thorez Avenue, Saint-Petersburg 194223, Russia.
International journal of molecular sciences
|January 23, 2024
概括
(CQ) 和基 (HCQ) 通过抑制自来增强化疗疗效的承诺. 虽然实验结果是积极的,但这些自抑制剂的临床试验结果仍然不一致.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- (CQ) 和 (HCQ) 是已知的自抑制剂.
- 癌细胞往往会对化疗和抗血管生成疗法产生抗性.
- 自调节被探索为克服治疗耐药性的策略.
研究的目的:
- 审查CQ/HCQ与常规化疗药物的联合应用.
- 总结CQ/HCQ作为辅助癌症治疗的实验和临床数据.
- 阐明癌细胞对CQ/HCQ反应的基础分子机制.
主要方法:
- 对培养癌细胞的体外研究进行审查.
- 使用动物异种移植模型进行体内研究的分析.
- 检查可用的临床试验数据.
主要成果:
- 大多数体外和体内研究表明,CQ/HCQ使癌细胞对细胞毒剂敏感.
- 在临床前模型中,与CQ/HCQ联合治疗表明化疗潜力增加.
- 癌症治疗中CQ/HCQ的临床试验结果显示存在不一致性.
结论:
- 使用CQ/HCQ的药理抑制自是一种增强化疗效的有希望的策略.
- 需要进一步研究和开发更具体的自抑制剂.
- 尽管临床发现不一致,但自抑制仍然是瘤学中宝贵的治疗途径.
相关概念视频
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
292
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
292
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


